IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that the Company will ...

A Washburn University student entered the Zeta Tau Alpha sorority house without permission the night of March 3 and was ...

IN8bio, Inc., a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies, has reported strong progress in its Phase 1 and Phase 2 clinical programs, showing ...

Adicet Bio specializes in the development of off-the-shelf gamma-delta T cell therapies for the treatment of cancer and autoimmune diseases. The company's innovative approach leverages the unique ...

Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, including glioblastoma ...

(RTTNews) - IN8bio, Inc. (INAB) announced the launch of its next-generation Gamma-Delta T-cell engager or TCE platform INB-600, designed to overcome the limitations of existing Gamma-Delta TCE ...

The Alpha Gamma Delta International Council informed university officials last month it was closing its Beta Alpha chapter of Alpha Gamma Delta, which was founded at Nebraska Wesleyan in 1927 ...

In the spirit of Women’s History Month, Hofstra University Greek organization Pi Lambda Phi hosted their second annual ...

Kelly Lasho, a Stone Ranch Elementary teacher, has received a $1,000 Anne Gillespie Innovative Grant to help her create the ...

Proprietary platform represents the first known approach capable of sustained gamma-delta T cell expansion, eliminating target cells with robust potencyINB-619, a next generation gamma-delta TCE targe ...